Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
02
02
2022
accepted:
21
03
2022
pubmed:
25
4
2022
medline:
7
7
2022
entrez:
24
4
2022
Statut:
ppublish
Résumé
National Comprehensive Center Network guidelines recommend radiotherapy (RT) omission in women age ≥ 70 years with estrogen receptor-positive (ER+), cN0, T1 tumors post-lumpectomy if they receive endocrine therapy (ET). However, little is known about the impact of poor adherence on locoregional recurrence (LRR) in elderly women forgoing RT. Women age ≥ 70 years with pT1-2 ER+ breast cancer undergoing lumpectomy without RT from 2004 to 2019 were identified from a prospectively maintained database. ET adherence, calculated as treatment duration over follow-up time up to 5 years, was determined by chart review. We compared clinicopathologic characteristics and rates of LRR between women with high adherence (≥ 80%), low adherence (< 80%), and no ET. Of 968 women (27 bilateral cancers), adherence was high in 676 (70%) and low in 162 (17%); 130 (13%) took no ET. Younger age and use of aromatase inhibitor were associated with high adherence. On multivariable analysis, tumor size (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03-2.68, p = 0.04) and high adherence (HR 0.13, 95% CI 0.07-0.26, p < 0.001) were significantly associated with LRR. At 53 months median follow-up, the 5-year rate of LRR was 3.1% (95% CI 2.4-3.9%) with high adherence, 14.7% (95% CI 11.7-17.7%) with low adherence, and 17.9% (95% CI 13.9-21.8%) with no ET (p < 0.01). Although adherence to ET was high overall, in the 30% of women with low adherence or no ET, LRR rates were significantly increased. Counseling regarding the distinct toxicities of ET and RT can help patients choose the therapy to which they will likely adhere to.
Sections du résumé
BACKGROUND
BACKGROUND
National Comprehensive Center Network guidelines recommend radiotherapy (RT) omission in women age ≥ 70 years with estrogen receptor-positive (ER+), cN0, T1 tumors post-lumpectomy if they receive endocrine therapy (ET). However, little is known about the impact of poor adherence on locoregional recurrence (LRR) in elderly women forgoing RT.
METHODS
METHODS
Women age ≥ 70 years with pT1-2 ER+ breast cancer undergoing lumpectomy without RT from 2004 to 2019 were identified from a prospectively maintained database. ET adherence, calculated as treatment duration over follow-up time up to 5 years, was determined by chart review. We compared clinicopathologic characteristics and rates of LRR between women with high adherence (≥ 80%), low adherence (< 80%), and no ET.
RESULTS
RESULTS
Of 968 women (27 bilateral cancers), adherence was high in 676 (70%) and low in 162 (17%); 130 (13%) took no ET. Younger age and use of aromatase inhibitor were associated with high adherence. On multivariable analysis, tumor size (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03-2.68, p = 0.04) and high adherence (HR 0.13, 95% CI 0.07-0.26, p < 0.001) were significantly associated with LRR. At 53 months median follow-up, the 5-year rate of LRR was 3.1% (95% CI 2.4-3.9%) with high adherence, 14.7% (95% CI 11.7-17.7%) with low adherence, and 17.9% (95% CI 13.9-21.8%) with no ET (p < 0.01).
CONCLUSIONS
CONCLUSIONS
Although adherence to ET was high overall, in the 30% of women with low adherence or no ET, LRR rates were significantly increased. Counseling regarding the distinct toxicities of ET and RT can help patients choose the therapy to which they will likely adhere to.
Identifiants
pubmed: 35461424
doi: 10.1245/s10434-022-11728-5
pii: 10.1245/s10434-022-11728-5
pmc: PMC10208089
mid: NIHMS1889614
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4753-4760Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Cancer Causes Control. 2017 Mar;28(3):215-225
pubmed: 28210883
J Clin Oncol. 2003 Feb 15;21(4):602-6
pubmed: 12586795
Breast Cancer Res Treat. 2020 Jan;179(1):217-227
pubmed: 31571072
Cancer. 2021 Jun 1;127(11):1749-1757
pubmed: 33496354
Breast Cancer Res Treat. 2018 Feb;167(3):615-633
pubmed: 29110151
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
Breast Cancer Res Treat. 2011 Apr;126(2):529-37
pubmed: 20803066
N Engl J Med. 2004 Sep 2;351(10):963-70
pubmed: 15342804
J Natl Cancer Inst. 2000 Apr 5;92(7):550-6
pubmed: 10749910
Breast Cancer Res Treat. 2019 Jun;175(3):733-740
pubmed: 30887164
J Natl Compr Canc Netw. 2008;6 Suppl 4:S1-25; quiz S26-7
pubmed: 18597715
N Engl J Med. 2005 Dec 29;353(26):2747-57
pubmed: 16382061
J Natl Cancer Inst. 2015 Jun 10;107(9):
pubmed: 26063794
Lancet. 1998 May 16;351(9114):1451-67
pubmed: 9605801
Br J Cancer. 2014 Mar 4;110(5):1378-84
pubmed: 24434426
Breast Cancer Res Treat. 2011 Sep;129(2):299-308
pubmed: 21594663
Breast Cancer Res Treat. 2010 Aug;122(3):843-51
pubmed: 20058066
J Clin Oncol. 2010 Sep 20;28(27):4120-8
pubmed: 20585090
J Clin Oncol. 2008 Feb 1;26(4):549-55
pubmed: 18071188
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
Expert Rev Anticancer Ther. 2018 Nov;18(11):1101-1112
pubmed: 30188738
Radiother Oncol. 2017 Apr;123(1):1-9
pubmed: 28391871
J Clin Oncol. 2002 Oct 15;20(20):4141-9
pubmed: 12377957
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
Cancer Med. 2020 Nov;9(22):8345-8354
pubmed: 32942344
Br J Cancer. 2013 Apr 16;108(7):1515-24
pubmed: 23519057
N Engl J Med. 2004 Sep 2;351(10):971-7
pubmed: 15342805
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Cancer. 2003 Nov 1;98(9):1802-10
pubmed: 14584060